An excellent response to BNCT treatment in head and neck cancerSeptember 14, 2004A Finnish research group has been the first in the world to publish an article in which BNCT treatment has had an excellent response in a patient with head and neck cancer for whom there was no other treatment available. The case report has been published in the June issue of the prestigious Radiotherapy and Oncology no. 72 (2004) pp. 83 - 84. BNCT treatment, which was developed for treating difficult brain tumours, has since last year also been given to patients with recurrent head and neck cancer for whom no other treatment is available. The treatment has been successful in improving the quality of life for patients with head and neck cancer. "Further research in this area has been prompted by encouraging results from patients with maxillary sinus cancer," says professor Heikki Joensuu, Helsinki University and the Department of Oncology at Helsinki University Central Hospital (HUCH). Joensuu is the Scientific Director of the BNCT research project funded by Boneca Corporation. "The successful treatment of head and neck cancer using BNCT has been proven effective by magnetic pictures and PET. The current research phase I/II aims to investigate the tolerance of BNCT treatment as well as aiming to find the effect of the treatment on the life span of patients with glioblastoma", Joensuu explains According to the Managing Director of Boneca Corporation, Markku Pohjola, the new research field is an excellent example of the high standard of Finnish BNCT reasearch and development. "Moreover, it shows how well the cooperation between Boneca and its partners, the Department of On-cology at Helsinki University Central Hospital (HUCH), the Technical Research Centre of Finland (VTT) and the Turku PET (Positron emission tomography imaging) Center, functions, " Pohjola continues. The aim is to conclude the current research as soon as possible. "By having offered a chance for cooperation to all university hospitals, we have also given a possibility for treatment to all Finnish patients who have expressed interest in experimental treatment and who have been suited for it," explains Joensuu. Boneca Corporation has also recently signed a contract of collaboration with Global Hospital, a chain of international private hospitals, so that BNCT treatment could also be offered to foreign patients. Helsingin yliopisto (University of Helsinki) |
|||||||||||||||||||||
| Related Cancer Current Events and Cancer News Articles Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. Does prostate-specific antigen velocity help in early detection prostate cancer? The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection. Key player identified in cascade that leads to hypertension-related kidney damage A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. New Notre Dame study provides insights into the molecular basis of tumor cell behavior A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression. Researcher: 'Optical biopsy' for breast cancer increasingly accurate But women may not have to endure the medical costs, stress and potential complications that accompany such invasive biopsies forever. A University of Florida biomedical engineering researcher is making progress on an "optical biopsy" that has the potential to determine whether growths are cancerous without ever puncturing the skin. Plastic surgeons offer microsurgery technique for breast reconstruction, tummy tuck after mastectomy Since her teens, Jennifer Jablon had watched family members deal with breast cancer during their 40s, 50s, and 60s. She wondered whether it would be her fate too. Newly revised guidelines for managing thyroid cancer published in Thyroid journal The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. Magnetic nanoparticles to simultaneously diagnose, monitor and treat Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as the life-dependant thumping of our hearts), mNPs have come a long way in the past decade. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||